Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Prevention |
RCV000253773 | SCV000310522 | benign | not specified | criteria provided, single submitter | clinical testing | ||
Labcorp Genetics |
RCV001515517 | SCV001723604 | benign | not provided | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001515517 | SCV001847383 | benign | not provided | 2019-08-20 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001838578 | SCV002098826 | benign | Focal segmental glomerulosclerosis 2 | 2021-09-10 | criteria provided, single submitter | clinical testing | |
Unidad de Genómica Garrahan, |
RCV000253773 | SCV005087475 | benign | not specified | 2024-07-15 | criteria provided, single submitter | clinical testing | This variant is classified as Benign based on local population frequency. This variant was detected in 67% of patients studied in a panel designed for Epileptic and Developmental Encephalopathy and Progressive Myoclonus Epilepsy. Number of patients: 62. Only high quality variants are reported. |
Breakthrough Genomics, |
RCV001515517 | SCV005236582 | benign | not provided | criteria provided, single submitter | not provided |